Panbela Therapeutics Inc. (PBLA)
(Delayed Data from OTC)
$0.40 USD
-0.01 (-2.44%)
Updated Apr 29, 2024 09:55 AM ET
2-Buy of 5 2
F Value B Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Panbela Therapeutics Inc. [PBLA]
Reports for Purchase
Showing records 21 - 40 ( 73 total )
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
With UK German Sites, All ASPIRE Sites Now Open - First Data Early 2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Divests Eflornithine in Pediatric Neuroblastoma For Up to Potential $9.5M
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
New Australian Patent Issued for Novel SBP-101 Production Process
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 ASPIRE Trial Gets the Green Light to Progress As Planned
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Successfully Passes DSMB Safety Review - Trial to Continue As Planned
Provider: Roth Capital Partners, Inc.
Analyst: AFTAHI D
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 PACES S0820 Trial Passes Pre-Planned Futility Analysis
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 PACES Trial Leaps Over Futility Hurdle, Paving the Way Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Releases Endocrine Society Poster for Eflornithine In Recent Onset T1D
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q23: Valuation Does Not Reflect Near- Term Potential Broad Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Panbela and MD Anderson Join Forces to Enhance CAR T Cell Therapy with Polyamines
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
News Flow Crunch Time With Risks; Post-Reverse Target to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Panbela and Moffitt Cancer Center Join Forces for NSCLC
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Plentiful Pipeline Advancements in the Year to Come
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Taking Aim to Break Down Polyamine Barriers; Initiating at Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
AACR Poster Shows Favorable Preclinical SBP-101/Chemotherapy Results
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Regains North American Flynpovi Rights From One-Two Therapeutics Assets
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J